Patents Assigned to QUARRYMEN&Co. Inc.
  • Patent number: 11510987
    Abstract: The present invention addresses the problem of providing an endocytosis enhancer comprising associates formed from a fluorescent protein. The fluorescent protein is preferably any one selected from the group consisting of a white fluorescent protein, a red fluorescent protein, a yellow fluorescent protein, a blue fluorescent protein and a green fluorescent protein. The endocytosis enhancer according to the present invention can enhance the cellular uptake of a drug, which is encapsulated in micelles each formed from a fluorescent-protein-supported carbosilane dendrimer, through endocytosis.
    Type: Grant
    Filed: August 7, 2019
    Date of Patent: November 29, 2022
    Assignees: Saitama University, QUARRYMEN & Co. Inc.
    Inventors: Miho Suzuki, Ken Hatano, Shojiro Yoshida, Yasuhiro Yamashita
  • Patent number: 11160877
    Abstract: The present invention relates to a targeting-type capsule for drug delivery systems. The present invention addresses the problem of providing a capsule for drug delivery systems by utilizing the reactivity of a thiol with an alkyl halide, wherein the capsule comprises a silole-containing carbosilane dendrimer and a labeling protein containing a target recognition site (e.g., green fluorescent protein), can include a biological polymer or another molecule therein, and can deliver the biological polymer or the like selectively into a target cell.
    Type: Grant
    Filed: November 27, 2018
    Date of Patent: November 2, 2021
    Assignees: Saitama University, QUARRYMEN & Co. Inc.
    Inventors: Miho Suzuki, Ken Hatano, Shojiro Yoshida, Yasuhiro Yamashita
  • Patent number: 11015171
    Abstract: The purpose of the present invention is to provide immortalized stem cells for producing culture supernatant that can be used in the treatment of human diseases. Provided is a method for producing immortalized stem cells, the method being provided with: a step for producing a DNA fragment that includes a telomerase reverse transcriptase and at least one gene selected from the group consisting of Bmi-1, human papilloma virus E6, and human papilloma virus E7; a step for producing a viral vector that incorporates the DNA fragment including the gene; a step for transfecting the viral vector into mammalian stem cells and introducing the gene into the stem cells; and a step for culturing the stem cells into which the gene was introduced and using a drug to select immortalized stem cells.
    Type: Grant
    Filed: May 1, 2018
    Date of Patent: May 25, 2021
    Assignee: QUARRYMEN & Co. Inc.
    Inventor: Yasuhiro Yamashita
  • Patent number: 10918726
    Abstract: The object of the present invention is to provide an aggregatable carrier material for drug delivery system and a micelle formed thereof. The present invention provides an aggregatable carrier material for drug delivery system, which is formed by utilizing the reaction between thiol group and alkyl halide. It is formed by using carbosilane dendrimers containing silole and labeled proteins such as green fluorescent protein in aqueous solvent or in mixed solvent of the aqueous solvent and organic solvent. The micelle composed of the material may incorporate compounds having a variety of molecular weight and biopolymers in the aqueous solvent.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: February 16, 2021
    Assignees: QUARRYMEN & Co. Inc., Saitama University
    Inventors: Miho Suzuki, Ken Hatano, Shojiro Yoshida, Yasuhiro Yamashita
  • Patent number: 10772973
    Abstract: The present invention is related to a targeted type shell for drug delivery system. The object of the present invention is to provide the targeted type shell for DDS, which comprises a carbosilane dendrimer containing a silole produced by which is formed by utilizing the reaction between thiol group and alkyl halide, and a targeted protein containing a labeled proteins such as green fluorescent protein with a target recognition site. The shell may incorporate compounds having a variety of molecular weight and biopolymers, and selectively deliver them into targeted cells.
    Type: Grant
    Filed: May 29, 2018
    Date of Patent: September 15, 2020
    Assignees: QUARRYMEN & Co. Inc., Saitama University
    Inventors: Miho Suzuki, Ken Hatano, Shojiro Yoshida, Yasuhiro Yamashita
  • Patent number: 10668261
    Abstract: The purpose of the present invention is to provide a sheet-like piece comprising; a base sheet comprising an elastic material; a reservoir layer provided on the surface of said base sheet which contains a physiologically active substance and comprises micro needles; a adhesion layer which is formed in a mesh form on said base sheet and; a adhesion assisting layer which is formed on the surface of opposite side of said base sheet to the surface formed said reservoir layer. As a result, the sheet for promoting hair growth which may restore the state of thin hair to a state before thinning, a whitening and wrinkle ameliorating agent having whitening effect and wrinkle improving effect, and sheet-like piece used for these are provided.
    Type: Grant
    Filed: October 23, 2017
    Date of Patent: June 2, 2020
    Assignee: QUARRYMEN&CO. INC.
    Inventors: Hiroshi Hochi, Yasuhiro Yamashita
  • Patent number: 10639355
    Abstract: The invention provides a novel anticancer therapeutic having a high effect against solid cancers, lacking the side effects of chemotherapeutics, and being unlikely to cause resistance. Provided is a pharmaceutical composition for cancer treatment prepared by a method having: a stem cell production step for making immortalized stem cells by introducing four types of genes into deciduous tooth dental pulp stem cells obtained from the dental pulp of mammals; and a condition medium preparation step for culturing the immortalized stem cells for a predetermined length of time in serum-free medium at 23-27° C. under conditions of low oxygen concentration at an oxygen concentration of from 0.5% to less than 20%, the pharmaceutical composition containing 1.5 times or more of insulin-like growth factor (IGF-1) and vascular endothelial growth factor (VEGF) than is contained in condition medium prepared when culturing at an oxygen concentration of 20% and otherwise identical conditions.
    Type: Grant
    Filed: January 23, 2015
    Date of Patent: May 5, 2020
    Assignee: QUARRYMEN & Co. Inc.
    Inventor: Minoru Ueda
  • Patent number: 10494606
    Abstract: The purpose of the present invention is to provide immortalized stem cells, which produce a growth factor capable of regenerating various kinds of tissues that have been damaged by a variety of causes, and a method for producing the aforesaid immortalized stem cells. Another purpose is to provide a medicinal composition and a medicinal preparation for restoring damaged tissues, and a method for the percutaneous absorption of a culture supernatant. Provided are immortalized stem cells that are obtained by isolating stem cells selected from the group consisting of mammalian mesenchymal cells, an embryo at the early stage of the development and somatic cells, first culturing the cells to give first stage culture cells, transferring four kinds of genes into the first stage culture cells to give transgenic cells, and selecting the desired immortalized stem cells from among the transgenic cells using the expression of STRO-1 as an index.
    Type: Grant
    Filed: June 26, 2017
    Date of Patent: December 3, 2019
    Assignee: QUARRYMEN&Co. Inc.
    Inventor: Minoru Ueda